Taking into account the proven influence of concomitant mutations on the outcome, the presence of the WT1 and NPM1 mutations was included in the stratification of the risk groups in the consecutive protocols (AML-BFM 2012 and AML-BFM 2019—second period). The gene discussed is WT1; the disease is acute myeloid leukemia.